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A unique glycopeptide, antiproliferative factor (APF), has been suggested as a urinary biomarker and potential mediator of long-
term bladder disorder Interstitial Cystitis/Painful Bladder Syndrome. There is no known cause for this disease. Several mechanis-
tic approaches have been employed to address the underlying mechanism whereby APF regulates cellular responses in the blad-
der epithelium. A summary of recent literature is provided, and is focused on signal transduction pathways and networks that 
are responsive to APF.
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INTRODUCTION
Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
A chronic bladder disorder, IC/PBS, affects over 1 out of 77 
Americans (3 to 8 million women and 1 to 4 million men). 
Clinopathological processes underlying this disease have not 
yet been elucidated, clinical biological markers of the condition 
are not available, and the type and severity of symptoms can 
vary. Consequently, an unambiguous clinical definition of the 
condition is not yet possible [1-8]. It is not understood whether 
IC/PBS is a systemic disease or whether it originates from the 
bladder and/or other pelvic organs [5,9]. Thus, IC/PBS is a con-
troversial subject and there is still much to be leaned about this 
disease [10].
Diagnosis
IC/PBS patients are generally diagnosed according to certain 
clinical criteria, such as National Institute of Diabetes and Di-
gestive and Kidney Diseases guidelines, which contain inclu-
sion clinical diagnostic criteria using symptoms combined with 
cystoscopic observations, in the absence of other bladder dis-
eases (e.g., overactive bladder, bacterial cystitis, neurogenic blad-
der, stress incontinence, urological cancer [bladder or prostate 
cancers], or benign prostatic hypertrophy, and chronic pelvic 
prostatic symptoms) [1,2,5,6,10-14]. Hydrodistension has been 
used as part of a diagnostic algorithm. Accumulating scientific 
data on diagnostics show that cystoscopy and hydrodistension 
may not be sufficiently sensitive or specific [13,14]. Other diag-
nostic tests can involve results from urine analysis, urine culture, 
biopsy of the bladder wall and urethra, specific questionnaires 
to assess the condition (e.g., pain score), the potassium sensitiv-
ity test, and/or the anesthetic bladder challenge [1,15,16]. How-
ever, there is no single diagnostic gold standard. In the absence 
of agreed-upon diagnostic tests, IC/PBS criteria have not been 
consistently applied for diagnosis in clinical medicine [4].
  Recently, new guidelines by the American Urological Associ-
ation (AUA) IC/PBS guidelines committee suggest a manage-
ment strategy for the IC/PBS patient [17]. This recommenda-
tion was based on an extensive literature review of 86 articles 
containing information on application of inclusion and exclu-
sion criteria toward IC/PBS patients. The AUA guidelines sug-
gest conservative, noninvasive approaches involving diet change, 
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physical therapy for symptom relief and stress management 
[8,16,17]. Overall, this recommendation outlines five levels of 
treatment, including pain management. 
Treatment
Treatment of IC/PBS remains challenging. Although medical 
treatments and procedures, such as bladder instillation, hydro-
distension, and oral pharmaceutical drugs are prescribed for 
those afflicted with the disease [1,13,17,18], these therapies are 
effective in only a small percentage of patients and most cause 
undesirable side effects [19]. Oral medications include pento-
san polysulfate (Elmiron), antihistamines, tricyclic antidepres-
sants, and immune modulators. Intravesical medications include 
dimethyl sulfoxide (DMSO), pentosan polysulfate, and heparin. 
Elmiron is the only oral therapy, and DMSO-based therapy is 
the only intravesical therapy, with Food and Drug Administra-
tion-approval for the treatment of IC/PBS [18]. The most com-
monly prescribed IC/PBS medication is Elmiron; however, 
symptom relief by this drug is only for 30 to 60% of patients. 
Side effects such as hair loss and gastrointestinal disturbance 
are commonly observed after treatment is initiated [18].
POTENTIAL BIOMARKERS OF IC/PBS
Since current IC/PBS diagnosis is generally based on symptoms 
and exclusion of other bladder disorders, identification of ob-
jective biomarkers, phenotyping and characterization of pathol-
ogy would represent a major advance [11,20-22]. Although 
there are substantial limitations and roadblocks to implement-
ing biomarker discovery, there is a tremendous need for specific 
and sensitive biomarkers in this field [9,15,23]. Biomarkers can 
be used for diagnosis and/or for tracking the treatment response 
of patients, which can reduce clinical burden. Biomarkers in 
urine or blood are favorable, since their application requires less 
invasive methods [23].
  Searches for an objective urinary IC/PBS biomarker have led 
to the identification of several candidates such as substance P, 
uroplakin III-δ4 mRNA, interleukin-6, cyclic guanosine mono-
phosphate, uromodulin, kininogens, inter-α-trypsin inhibitor 
heavy chain H4, nitric oxide, nerve growth factor, heparin-bind-
ing epidermal growth factor-like growth factor (HB-EGF) and 
antiproliferative factor (APF) [15,24-33]. There are still a lot of 
discrepancies on strong correlation to severity (e.g., pain and 
symptom score), clinical course and responsiveness to treat-
ments (e.g., steroid or oral prednisolone) in IC/PBS patients, 
compared to their age-, race- and gender-matched controls. 
HB-EGF, EGF and APF 
Three urinary biomarkers identified from IC/PBS patient mate-
rial were found by Keay et al. [25,34]: epidermal growth factor 
(EGF) and APF concentrations in urine were positively corre-
lated with presence of disease, while HB-EGF exhibited an in-
verse correlation in urine of IC/PBS patients, compared to con-
trols (urine from patients without IC/PBS).
  EGF and HB-EGF are potent urothelial and smooth muscle 
cell mitogens, and enhance proliferation [35,36]. EGF is a prod-
uct of many epithelial cells and was the first activating ligand 
for the epidermal growth factor receptor (EGFR) identified [37]. 
HB-EGF is initially expressed as a transmembrane precursor 
(proHB-EGF), with the soluble form generated by the regulated 
metalloproteinase-dependent ectodomain shedding. Secreted 
soluble HB-EGF activates mitogenic and cell survival functions, 
while proHB-EGF acts as a juxtacrine factor and also mediates 
translocation of diphtheria toxin from the cell surface to the cy-
tosol. In addition to activation of the EGFR, HB-EGF is also a 
direct activating ligand for the related tyrosine kinase, ErbB4/
HER4 [36,38]. EGF and HB-EGF are present under normal 
conditions in human urine, and the levels are altered in patients 
with IC/PBS [25,34]. Concentrations of HB-EGF and EGF 
change in an inverse manner (EGF levels are higher and HB-
EGF levels are lower) in IC/PBS patients [34].
  APF is a small, 8 amino acid sialoglycosylated peptide identi-
fied in IC/PBS patients. Bioactivities attributed to APF include: 
suppression of cell growth; increases of transcellular permeabil-
ity; lowering of the expression of proteins that form intercellular 
junctional complexes; and reduction of HB-EGF production 
from urothelial cells [39]. APF is originally purified from the 
urine specimens of IC/PBS patients using high performance liq-
uid chromatography [24,40,41], and recently a bioactive, syn-
thetic form of the glycopeptide was reported [42]. APF activity 
is detected in the urine of approximately 95% of IC/PBS patients 
(as compared to approximately 9% of controls).
APF AND IC/PBS
The accumulation in urine of the bioactive factor APF, which is 
capable of altering the physiology and behavior of urothelial 
cells, is consistent with clinical observations of epithelial thin-
ning and denudation observed in IC/PBS bladder tissue. In vi-
tro, APF is synthesized and secreted from bladder epithelial cells 186    www.einj.or.kr
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derived from patients diagnosed as IC/PBS, but not from as-
ymptomatic controls [41]. APF is 100% homologous to the 6th 
transmembrane domain of membrane receptor frizzled-8, in 
the Wnt signaling network. APF is acidic, heat-stable and gly-
cosylation is required for biological activity. The structure of 
APF (Neu5Acα2-3Galβ1-3GalNAcα-O-TVPAAVVVA) was 
deduced by a series of processing steps, involving ion trap mass 
spectrometry, enzymatic digestion, lectin affinity chromatogra-
phy, and microcapillary reversed-phase liquid chromatography/
mass spectrometry (MS) [24]. 
  Both chemically synthesized and native APF (purified from 
urine or explants from biopsies from patients with IC/PBS) had 
identical biological activity in normal bladder epithelial cells and 
several types of cancer cells including T24 bladder cancer cells 
[24,42,43]. These findings suggest that APF is not only a urinary 
biomarker but also a potential mediator of the pathogenic 
changes seen in IC/PBS. 
APF SIGNALING
In order to determine the potential etiologies of IC/PBS, and to 
identify molecular and cellular differences between IC/PBS pa-
tients and controls, understanding the molecular mechanisms 
of the various effects induced by APF has been attempted. De-
nudation or thinning of the epithelium is commonly observed 
in bladder biopsies from patients with IC/PBS, suggesting cell 
proliferation is hindered in IC/PBS cells [40,44]. Although the 
exact etiology is unknown, the impermeability of the bladder 
barrier is increased, resulting in a leaky bladder epithelium and 
potassium leakage, potentially a source of origin for IC/PBS 
symptoms (such as frequency, urgency, pelvic pain or inconti-
nence) [45]. Additional bladder dysfunction includes increased 
nerve fiber density and inflammatory infiltrates (e.g., mast cell 
and/or lymphocytic), which are correlated to the increased pain 
and cytokine production in IC/PBS bladder [46-48]. To under-
stand the underlying mechanisms, several laboratories have fo-
cused on abnormal cell signaling induced in presence of APF in 
bladder epithelial cells. As we will discuss below, these led to the 
following observations that 1) cytoskeleton-associated protein 4 
(CKAP4 or CLIMP63) plays a role as an APF receptor [42,49, 
50]; 2) the palmitoylation status of CKAP4 is important for APF 
signal transduction [39,49]; 3) mitogen-activated protein kinase 
(MAPK) signal pathways were altered by APF [39,51]; 4) phos-
phorylation of Akt and its target, glycogen synthase kinase (GSK), 
is induced by APF treatment [42,52]; 5) the p52-p21 signal 
pathway is enhanced in the presence of APF, leading to inhibi-
tion of cell proliferation [52]; and 6) a quantitative proteomics 
analysis and bioinformatics identified β-catenin as a prominent 
hub molecule in APF-induced signaling [53].
APF Receptor, CKAP4/CLIMP63
Zhang et al. [54] found that APF binds to a high affinity cell 
surface receptor, CKAP4/CLIMP63, which mediates APF sig-
naling in bladder epithelial cells, using the palmitoyl-cysteine 
identification capture and analysis method. In general, palmi-
toylation (S-acylation) of transmembrane proteins regulates 
subcellular trafficking and/or protein degradation [55]. S-acyla-
tion of CKAP4/p63 is required for its proper localization into 
the plasma membrane by Asp-His-His-Cys protein (DHHC), a 
specific palmitoyl acyltransferase and a putative tumor suppres-
sor [54]. APF binds to membrane resident palmitoylated CKAP4, 
resulting in an inhibition of cell proliferation and alteration of 
the expression of genes relevant to cell-to-cell permeability (e.g., 
E-cadherin, vimentin, and tight junction protein, ZO-1) [54,56]. 
Interestingly, DHHC2-mediated CKAP4/p63 palmitoylation 
mediates CKAP4/p63 trafficking from the ER to the surface 
membrane and/or to nucleus, suggesting that DHHC2 activity 
is critical to the APF-mediated signaling requiring CKAP4/p63 
[49,55]. The potential correlation of expression of CKAP4/p63, 
DHHC2 and sensitivity to APF remains to be tested. 
MAPK Signal Pathways
Various biological responses in response to APF accompany the 
perturbed signal transduction pathways [39]. The possible role 
of the MAPK pathways (including Erk/MAPK, p38MAPK, and 
c-Jun N-terminal kinases/stress-activated protein kinase [JNK/
SAPK] signaling) in IC/PBS are not well understood, in spite of 
importance of MAPK signaling in epithelial, endothelial, and 
fibroblast cell proliferation [57,58]. Although there are impor-
tant differences between tissues and cell types, Erk, p38 and 
JNK/SAPK MAPK pathways often exert opposing functions 
and undergo extensive cross-talk in regulating proliferation and 
cell death. 
  APF treatment has been reported to result in the increased 
p38MAPK phosphorylation and suppressed cell growth, which 
were both reversed by a p38MAPK-selective inhibitor [51]. Very 
recently, Li et al. [59] reported that a transcription factor in the 
JNK/SAPK pathway, c-Jun, involves in growth suppression by 
APF. APF also induced a significant decrease in c-Jun expres-
sion in concert with growth inhibition. Enforced c-Jun expres-www.einj.or.kr    187
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sion reversed APF inhibitory effects on cell growth. These re-
sults show that JNK/SAPK expression may also be important 
for control of uroepithelial cell proliferation, with JNK1 levels 
decreased in both IC/PBS cells (compared to controls) and APF-
treated normal bladder epithelial cells (compared to control 
peptide-treated) [45,59]. 
Akt Pathway
Activation of the a serine-threonine kinase, Akt/protein kinase 
B, is generally important to cell proliferation, migration and 
survival [60-62]. There are three isoforms, Akt1, Akt2, and Akt3, 
which show differential functions in cancer cells [62,63]. Phos-
phorylation of Akt/PKB occurs at Ser473 and Thr308 [61-63]. 
Recent studies have shown that the rapamycin-insensitive ric-
tor-mTOR complex (mTORC2) and DNA-dependent protein 
kinase both directly phosphorylates Akt at Ser473 [64,65]. How-
ever, it has not been shown whether Akt or Akt-related mole-
cules (e.g., PI3-Kinase and GSK) are related to IC/PBS, except a 
very recent paper showing that APF treatment downregulates 
Akt signaling in bladder epithelial cells [42]. Phosphorylation 
of Akt (at Ser473 and Thr308), GSK3β (at Tyr216) and β-catenin 
(at Ser45/Thr41) were decreased by APF treatment, suggesting 
that APF downregulates Akt and its downstream signaling net-
work, which is consistent with the growth arrest observed in 
IC/PBS cells. It has not been tested whether this downregula-
tion of Akt signaling in response to APF is dependent on PI3-
kinase or the PTEN pathway, which is an important upstream 
inhibitor of Akt signaling [66,67].
p53-p21 Signaling
Activation of the p53 pathway is stimulated by stress signals 
(such as DNA damage and oxidative stress) and activated onco-
genes [68-70]. As a transcription factor, p53 controls the expres-
sion of p53-regulated genes [71,72], resulting in cell cycle arrest, 
cellular senescence, apoptotic cell death, or repair of damaged 
DNA [73,74]. Loss of p53 function is one of the common ge-
netic alterations observed in human cancer cells [73,75,76].
  The signaling mechanisms by which APF induces its anti-
proliferative activity are of considerable interest. Treatment of 
normal human urothelial cells, and T24 human bladder carci-
noma cells with APF increased p53 levels [52]. Changed p53 
level altered the APF effect on cell growth, indicating that p53 is 
involved in the mechanism of APF-induced growth suppression 
observed in the context of IC/PBS. p53 down-regulation en-
hanced the suppressive effect of APF on cell growth, while ecto-
pic p53 expression induced cell cycle arrest in the absence of 
APF. One of the p53 targets, p21 was induced by APF treatment 
in presence of p53, implying that p53-p21 signaling is an im-
portant mediator of APF–induced effects on bladder epithelial 
cells [52]. Some p53-interacting proteins, including herpesvi-
rus-associated ubiquitin-specific protease, homeodomain-in-
teracting protein kinase 2, ataxia telangiectasia mutated (ATM), 
ATM and RAD3-related, and heterogeneous nuclear ribonu-
cleoprotein K, are known to stabilize p53 and increase expres-
sion level [68,77-80]. Phosphorylation of p53 at specific sites 
protects p53 from degradation by murine double minute [81,82]. 
However, the specific mechanism by which APF regulates p53 
and p21 levels in the IC/PBS context is not clearly understood. 
Additional studies on the p53 modification status in response 
to APF remain to be undertaken. 
β-catenin in IC/PBS
In order to identify IC/PBS-specific pathogenetic mechanisms 
and biomarkers, efforts have been focused on genomic, pro-
teomic and metabolomic patterns to distinguish IC/PBS from 
other bladder diseases. These studies were often combined with 
a systems-biology approach with microarray, MS and proton 
nuclear magnetic resonance (1H-NMR)-based spectral patterns 
[45,83]. 
  Over about 100 significantly changed proteins following APF 
treatment were identified by stable isotope labeling by amino 
acids in cell culture (SILAC) quantitative proteomics [53]. 
β-catenin was found to be the most prominent and functionally 
relevant protein in the APF signaling network by various func-
tional validation assays. Bioinformatics analysis with data inte-
gration of the in vitro SILAC data with in vivo RNA expression 
data obtained from IC/PBS patients identified cyclooxygenase-2 
(COX-2) as an effector of β-catenin in IC/PBS. In bladder epithe-
lial cells from IC/PBS patients, the expression level of β-catenin 
was correlated to level of COX-2 [53]. These findings suggest 
that inflammation associated with IC/PBS may be caused, at 
least in part, by APF. These findings imply that targeting the 
β-catenin-COX-2 signaling pathway in addition to APF may be 
a rational approach toward treating IC/PBS.
THERAPEUTIC IMPLICATION OF APF 
RESEARCH
HB-EGF as an APF Antagonist
One interesting feature of the existing urinary biomarkers of 188    www.einj.or.kr
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IC/PBS is the functional relationship between APF and HB-
EGF. First, levels of these two biomarkers are inversely correlat-
ed in IC/PBS patient urine [25,41]. Second, this inversed pat-
tern has been observed after cystoscopic hydrodistention, a 
common clinical procedure to relieve IC/PBS-related symp-
toms. Application of hydrodistention significantly increased 
HB-EGF levels and decreased APF activity in urine [84]. Third, 
APF was shown to decrease HB-EGF production by normal 
human bladder epithelial cells in vitro, and concentrations of 
recombinant human HB-EGF, similar to those found in normal 
human urine specimens, were shown to abrogate the effects of 
APF on human bladder epithelial cells [40]. Lastly, removal of 
APF from the culture medium induced HB-EGF production 
and recovery of cell proliferation [51]. Together, these results 
suggest that HB-EGF and APF are functionally antagonistic 
biopeptides. 
  Further investigation on the underlying mechanisms of the 
bioactivity relationship between HB-EGF and APF has revealed 
the involvement of signal transduction pathways perturbed by 
them. HB-EGF and APF are functionally antagonistic due to 
signals through parallel MAPK signaling pathways: activated 
Erk/MAPK by HB-EGF is inhibited by APF, and APF cannot 
stimulate p38MAPK in the presence of soluble HB-EGF (or 
when cells overexpressed constitutively secreted HB-EGF) [51]. 
  Although the mechanism of the hydrodistention effect has 
not been clearly known hydrodistension therapy has been in-
troduced to relief IC/PBS symptoms [14]. IC/PBS symptom 
scores were decreased 56% in a cohort of patients after hydro-
distension [14]. One suggested hypothesis is that bladder dis-
tention may increase the capacity to reduce pain signals trans-
mitted by the nervous system. Hydrodistention also results in 
an increase of HB-EGF levels in urine and a reduction of urine 
APF activity [84]. The functional correlation of APF and HB-
EGF through crosstalk between signal pathways provides a 
mechanistic basis for the reported therapeutic effects of hydro-
distension to relief IC/PBS symptoms, one consequence of which 
is increased intraluminal concentrations of HB-EGF, an APF 
antagonist.
Inactive APF Derivatives 
Chemically synthesized asialylated APF (as-APF) exhibited 
similar antiproliferative effects on normal bladder epithelial 
cells. Removal of the sialic acid unit from as-APF did not affect 
its biological activity. Over 40 synthetic APF analogues were re-
cently screened to identify inactive APF derivatives for their 
ability to block antiproliferative activity of as-APF in normal 
bladder cells [43]. Two inactive as-APF derivatives, D-proline 
as-APF, Galβ1-3GalNAcα-O-TV-(d-pipecolic acid)-AAVVVA, 
and D-pipecolic acid as-APF, Galβ1-3GalNAcα-O-TV-(d-
proline)-AAVVVA were found to block as-APF antiprolifera-
tive activity in normal bladder epithelial cells. Furthermore, 
these as-APF derivatives were able to recover the altered tight 
junction protein expression, paracellular permeability, and/or 
proliferation of IC/PBS cells [43]. 
CONCLUDING REMARKS 
The purpose of this review was to revisit the published literature 
showing evidence for a biological role of APF in IC/PBS, with a 
focus on APF-induced gene expression and signaling network 
alterations. We also discuss some potential therapeutic strate-
gies for this bladder disorder based on the functions of APF an-
tagonists.
  Clinical diagnosis of IC/PBS largely relies on the exclusion of 
other bladder diseases. Pathologic and biologic tools for diag-
nosis are sorely needed. However, it is encouraging that IC/PBS 
biomarkers have been identified in patient urine, suggesting 
that non-invasive methods using quantitative and accurate di-
agnostic criteria may be possible. Our understanding of the ori-
gins and molecular mechanisms of this debilitating disease are 
limited and contradictory. Much work needs to be undertaken 
to refine the currently existing candidate biomarkers. Ongoing 
efforts in the IC/PBS field include mechanistic studies to en-
hance our understanding of etiology and disease progression, 
and to develop IC/PBS drugs using the inactive analogues of 
APF. Accumulating evidence also suggests the potential for APF 
signaling network-targeting therapy and deserves greater ex-
perimental attention.
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